Testing the abuse liability of anxiolytic and hypnotic drugs in humans
References (81)
- et al.
Effects of response requirement upon human sedative self-administration and drug-seeking behavior
Pharmacol. Biochem. Behav.
(1976) - et al.
Reinforcing properties of lorazepam in normal volunteers
Drug Alcohol Depend.
(1984) - et al.
Reinforcing and subjective effects of diazepam in nondrug-abusing volunteers
Pharmacol. Biochem. Behav.
(1989) - et al.
Lack of preference for flurazepam in normal volunteers
Pharmacol Biochem. Behav.
(1984) - et al.
Individual differences in the reinforcing and subjective effects of amphetamine and diazepam
Drug Alcohol Depend.
(1986) - et al.
Relative abuse liability of lorazepam and diazepam: an evaluation in ‘recreational’ drug users
Drug Alcohol Depend.
(1988) - et al.
Investigation of the abuse liability of buspirone in alcohol-dependent patients
Am. J. Med.
(1986) - et al.
Diazepam dose preference in humans
Pharmacol. Biochem. Behav.
(1983) - et al.
Abuse liability assessment in human subjects
Trends Pharmacol. Sci.
(1984) - et al.
Repeated administration of diazepam and triazolam to subjects with histories of drug abuse
Drug Alcohol Depend.
(1986)
Preference for alprazolam as opposed to diazepam in benzodiazepine-dependent psychiatric inpatients
Pharmacopsychiatry
Longterm treatment with diazepam
Int. Pharmacopsychiatry
Comparison of the reinforcing properties of zopiclone and triazolam in former alcoholics
Pharmacology
Euphoria, dysphoria. Measurement of Subjective Responses
Studies on the dependence-inducing potential of zopiclone and triazolam
Pharmacology
Drug deprivation and reinforcement by diazepam in a dependent population
Psychopharmacology
Benzodiazepines as drugs of abuse and dependence
Parental alcoholism as a risk factor in benzodiazepine abuse: a pilot study
Am. J. Psychiatry
Abuse liability and clinical phar-macokinetics of alprazolam in alcoholic men
J. Clin. Psychiatry
Critical review of liability for benzodiazepine abuse among alcoholics
Am. J. Psychiatry
Assessment of the abuse liability of buspirone in recreational sedative users
J. Clin. Psychiatry
A drug preference procedure for use with human volunteers
Assessing pentobarbital preference in normal volunteers using a cumulative dosing procedure
Psychopharmacology
Lack of preference for diazepam in anxious volunteers
Arch. Gen. Psychiatry
Drug preference in normal volunteers: effects of age and time of day
Psychopharmacology
The reinforcing properties of amphetamine in overweight subjects and subjects with depression
Clin. Pharmacol. Therapeut.
Preference for pentobarbital and diazepam in normal volunteer subjects
Patterns of benzodiazepine use in Great Britain as measured by a general population survey
Br. J. Psychiatry
Zolpidem and triazolam in humans: Behavioral and subjective effects and abuse liabiity
J. Pharmacol. Exp. Therapeut.
Preference studies of triazolam with standard hypnotics in out-patients with insomnia
J. Int. Med. Res.
The assessment of the abuse potentiality of sedative/hypnotics (depressants) (methods used in animals and man)
Methods for evaluating addiction liability. (A) ‘Attitude’ of opiate addicts toward opiatelike drugs, (B) A short-term ‘direct’ addiction test
J. Pharmacol. Exp. Therapeut.
Human drug self-administration: double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo
J. Pharmacol. Exp. Therapeut.
Similarities in animal and human drug-taking behavior
Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo
J. Pharmacol. Exp. Therapeut.
Human sedative self-administration: effects of interingestion interval and dose
J. Pharmacol. Exp. Therapeut.
Differential effects of diazepam and pentobarbital on mood and behavior
Arch. Gen. Psychiatry
Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects
Psychopharmacology
Comparison of diazepam and oxazepam: preference, liking and extent of abuse
J. Pharmacol. Exp. Therapeut.
Abuse liability of benzodiazepines: a review of human studies evaluating subjective and/or reinforcing effects
Cited by (154)
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling
2022, NeuropharmacologyCitation Excerpt :Developing and validating these models would seem best done through a collaboration involving NIDA, FDA, and leading clinical research organizations (CROs) with experience conducting pivotal studies with diverse substances and including input and oversight from an outside Expert Panel of researchers, clinicians, ethicists, and diverse community representatives to develop a modified psychedelic HAP (mp-HAP) approach. Decades of study with variations on the currently recommended HAP model indicates that these studies can substantially advance the understanding of mechanisms of drug action as well as effects that promote use (Jasinski et al., 1984; Jasinski and Henningfield, 1989; de Wit and Griffiths, 1991; Expert Panel, 2003; Griffiths et al., 2003; Carter and Griffiths, 2009). However, as discussed in this article elements of HAP design recommended in FDA’s 2017 Guidance may not be safe and its focus on peak liking may not capture the diverse effects of psychedelics that may serve both to limit compulsive use and abuse, but may also contribute to reasons for use beyond getting high and experiencing euphoria.
Subjective responses predict d-amphetamine choice in healthy volunteers
2021, Pharmacology Biochemistry and BehaviorClinical Evaluation of Abuse Potential for New Pharmaceuticals: The Assessment of Abuse Potential during Drug Development
2015, Nonclinical Assessment of Abuse Potential for New PharmaceuticalsOpioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testing
2013, Drug and Alcohol DependenceCitation Excerpt :This phenomenon is not limited to opioids. Evidence exists that some drug abusers fail to differentiate between placebo and amphetamine (Shram et al., 2011; Johanson and Preston, 1998; Duke et al., 2011), and similarly sedatives (De Wit and Griffiths, 1991). Future studies may examine other drug classes (e.g., cannabinoids) for this phenomenon and attempt to determine if the current results would be replicated in prescription opioid abusers (vs. the mixed prescription opioid and heroin users in the present study).
Do initial responses to drugs predict future use or abuse?
2012, Neuroscience and Biobehavioral Reviews